Gossamer Bio Q2 net loss $42.5M; raises $212M in July private placement

Gossamer Bio, Inc.

2023-Q2 EPS reported -$0.96

Net loss $42.5M ($0.45/share) vs $56.5M ($0.74) in Q2 2022; R&D expenses decreased to $36.3M.
Cash, equivalents & marketable securities $162.1M as of June 30; pro forma for July placement total $374M.
Phase 3 PROSERA study of seralutinib in PAH expected to start in Q3 2023; primary endpoint 6MWD at week 24.
Additional TORREY open-label extension data expected in Q4 2023 or Q1 2024.
July private placement raised ~$212M gross from sale of shares and warrants to institutional investors.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Gossamer Bio, Inc. reported the second quarter ended June 30, 2023 results: net income Net loss for the quarter ended June 30, 2023, was $42.5 million, or $0.45 per share, EPS $0.45 per share.

Period: the second quarter ended June 30, 2023
Net income: Net loss for the quarter ended June 30, 2023, was $42.5 million, or $0.45 per share
EPS: $0.45 per share
Result: reported results

Exact text from the filing

On August 8, 2023, Gossamer Bio, Inc. (the “Company”) issued a press release reporting its financial results for the quarter ended June 30, 2023.

View on SEC.gov

3 earnings releases filed in the last 30 days. Browse all earnings releases →

Gossamer Bio, Inc. filing history →

Source: SEC EDGAR

accession 0001728117-23-000107

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.